avutometinib (VS-6766)

Phase 2

Verastem, Inc. (VSTM)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

VSTMPhase 2$362M

Avutometinib (VS-6766) Phase 2 Est. Readout

avutometinib (VS-6766)• Low Grade Ovarian Serous Adenocarcinoma40

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Low Grade Ovarian Serous Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Low Grade Ovarian Serous Adenocarcinoma

Clinical Trial

NCT04625270

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VSTM

Verastem, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

avutometinibPhase 3

Low Grade Serous Ovarian Cancer

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2

KRAS Activating Mutation

Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2

Low Grade Serous Ovarian Cancer

defactinib (VS-6063)Phase 2

Non Small Cell Lung Cancer

VS-7375Phase 2

Pancreatic Ductal Adenocarcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts